Biomerica (BMRA) Common Equity (2011 - 2026)

Biomerica (BMRA) has 16 years of Common Equity data on file, last reported at $3.3 million in Q1 2026.

• For the quarter ending Q1 2026, Common Equity fell 40.06% year-over-year to $3.3 million; the trailing twelve-month figure through Feb 2026 stood at $3.3 million (down 40.06% YoY), and the FY2025 full-year result was $4.1 million, down 37.72% from the prior year.
• Common Equity retreated to $3.3 million in Q1 2026, from $4.4 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $11.7 million in Q2 2023 to a low of $3.3 million in Q1 2026.
• A 5-year average of $7.0 million and a median of $6.6 million in 2024 frame the typical range for Common Equity.
• Across the five-year window, Common Equity surged 40.83% in 2023 and slumped 50.35% in 2024, its largest moves.
• Tracing BMRA's Common Equity over 5 years: stood at $7.2 million in 2022, then rose by 29.53% to $9.4 million in 2023, then sank by 45.5% to $5.1 million in 2024, then dropped by 13.28% to $4.4 million in 2025, then dropped by 25.21% to $3.3 million in 2026.
• Business Quant data shows BMRA's Common Equity at $3.3 million in Q1 2026, $4.4 million in Q4 2025, and $5.2 million in Q3 2025.